About Pasithea Therapeutics Corp. - Common Stock (KTTA)
Pasithea Therapeutics Corp is a biotechnology company focused on the development of innovative therapies for the treatment of psychiatric and neurological disorders. The company is committed to leveraging advanced scientific research and cutting-edge technologies to create new treatment options that address unmet medical needs in these challenging areas. Pasithea aims to improve the quality of life for patients suffering from conditions such as depression and anxiety by exploring novel approaches in drug discovery and development. Through its work, Pasithea seeks to make a meaningful impact on mental health care and enhance overall well-being in affected individuals. Read More
Kartoon Studios (NYSE: TOON) announced significant momentum across its global content ecosystem as Mainframe Studios, Toon Media Networks, and its high-profile IP pipeline continue to fuel long-term growth.
After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Stay up-to-date with the latest market trends one hour before the close of the markets on Friday. Explore the top gainers and losers during today's session in our detailed report.
Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
The company saw increased retail chatter after new preclinical data showed its drug, PAS-004, effectively blocks inflammation pathways linked to IBD and other immune diseases.
The offering comes on the heels of encouraging data from the Virage Phase 2b trial, which demonstrated significant improvements in overall survival and duration of response for patients receiving Theriva's lead product candidate, VCN-01.
Curious to know what's happening on the US markets in the middle of the day on Wednesday? Join us as we explore the top gainers and losers in today's session.
